Comparative Pharmacology
Head-to-head clinical analysis: ANADROL 50 versus STANOZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANADROL 50 versus STANOZIDE.
ANADROL-50 vs STANOZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anabolic steroid; binds to androgen receptors, increasing protein synthesis and promoting nitrogen retention, leading to muscle growth and erythropoietin production.
Androgen receptor agonist; increases protein synthesis and muscle mass by binding to androgen receptors, leading to enhanced nitrogen retention and erythropoiesis.
Adults: 50-200 mg orally once daily for 2-6 weeks, then 2-4 weeks off. Not for continuous use.
100 mg orally twice daily or 200 mg orally once daily; immediate-release formulation.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours for parent drug; active metabolite 17α-methyl-5α-androstan-3α,17β-diol has half-life ~12-18 hours. Requires multiple daily dosing.
Terminal elimination half-life is 24-30 hours, supporting once-daily dosing. Clinical context: Steady-state achieved after approximately 5-7 days.
Primarily renal: 90% as glucuronide and sulfate conjugates; 6% fecal; <3% unchanged.
Primarily hepatic metabolism (approximately 80%) with biliary excretion of metabolites; renal excretion of unchanged drug is minimal (<5%). Fecal elimination accounts for <15%.
Category C
Category C
Anabolic Steroid
Anabolic Steroid